# Latent Tuberculosis in Type 2 Diabetes

> **NCT06874725** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Taichung Veterans General Hospital** · enrollment: 552 (actual)

## Conditions studied

- Latent Tuberculosis Infection

## Interventions

- **DRUG:** Rifapentine and Isoniazid for 3 months
- **DRUG:** Isoniazid (INH) daily for 9 months

## Key facts

- **NCT ID:** NCT06874725
- **Lead sponsor:** Taichung Veterans General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-18
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-04-18
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06874725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06874725, "Latent Tuberculosis in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06874725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*